PharmaTalkRadio

Evaluating single cell omics to understand the heterogeneity in immune and tumor cellsMulti-omic biomarkers for patient selection in solid tumor IO: is there a path to more personalized therapy?In an era of ‘targeted’ therapies against cell-intrinsic mechanisms (e.g. PARP, NTRK, BRAF) and surface molecules (Nectin-4, HER2), is there a path forward for pan-tumor biomarkers, or is multi-tumor more likely to be the dominant development mechanism?

Moderated by:

Theresa LaVallee, PhD, VP, Translational Medicine and Regulatory Affairs, Parker Institute for Cancer Immunotherapy

Panelists:

Jared Lunceford, PhD, Distinguished Scientist, Biostatistics and Research Decision Sciences, Merck Research LaboratoriesAngel A Rodriguez, MD, Oncology Medical Director, NateraSamik Upadhaya, PhD, Research Analyst, Anna-Maria Kellen Clinical Accelerator and Venture Fund, Cancer Research Institute (CRI)

Learn more about the IO360° Summit at www.io360summit.com

In this podcast, you will hear a presentation from Dr Barbara Lueckel, Roche Pharma Partnering, from the 2021 PODD Conference summarizing trends, approvals and pipelines within the drug delivery space.

To learn more about the PODD Conference, please visit PODDConference.com.

Dan Chen, MD, PhD, Founder, Engenuity Life Sciences

Learn more about the IO360° Summit at www.io360summit.com

This panel, first recorded at the 2022 IO360° Summit, reported on advances in achieving more diversity and inclusion in oncology clinical trials.

Moderated by:

Adrelia Allen, PharmD, Director, Clinical Trial Patient Diversity, Global Clinical Trial Operations, Merck Research Labs

Panelists:

Chétna Rao, PhD, Head of Site Strategy and Operations, BMSRobert Vonderheide, MD, DPhil, Director, Abramson Cancer Center, Perelman School of Medicine, University of PennsylvaniaKaren Peterson, Patient Advocate and Founder, Karen’s ClubMichel Reid, Sr. Director and Head, Global Demographics & Diversity, Global Clinical, Delivery, Global Clinical Operations, R&D, GSK

Learn more about the IO360° Summit at www.io360summit.com

About The Episode

With pharma’s focus on the extension of drug release windows, new technologies are needed that can lengthen that duration. Today, Zach Fletcher of Trelleborg Healthcare & Medical provides an insight into how the emerging field of long-acting implantables & polymeric drug delivery can address that need.

He will be addressing: current applications of implantables and likely future applications, top concerns from pharma and assessing your portfolio for lifecycle applications, manufacturing and scalability challenges, likely conversations around reimbursement from payers.

About the Speaker: 

Zach Fletcher, Business Development Manager - Implantable Drug Delivery & Combo Products at Trelleborg Healthcare & Medical

Zach Fletcher is the Business Development Manager - Implantable Drug Delivery & Combo Products at Trelleborg Healthcare & Medical. In this role, he identifies, establishes and develops relationships with device organizations and pharmaceutical companies to deliver unique solutions and therapies to patients. Trelleborg is a world leader in engineered polymer solutions that seal, damp and protect critical applications in demanding environments.

 

For more information on drug delivery news and partnership opportunities, click here.

CAR T cells for solid tumors: Lessons learned from on-going clinical trials in glioblastoma.Interplay between CAR T cells and the endogenous immune systemNext-generation CAR designs to overcome barriers for solid tumor CAR therapy

Christine Brown, PhD, Deputy Director, T Cell Therapeutics Research Laboratory, Beckman Research Institute, City of Hope

Learn more about the IO360° Summit at www.io360summit.com

When Claas Röhl’s 12-year old daughter was an infant, she was diagnosed with Neurofibromatosis Type 1 (NF), a rare genetic disorder that causes tumors to form along nerves. With no prior background in research, Claas founded NF Kinder and became an advocate for his daughter and patients impacted by this rare disorder. Claas will discuss his involvement in research, how he helped set up the first pediatric department for NF at a major medical University in Austria, and his efforts to create a national registry of NF patients. He will share lessons learned and offer insights on how best to engage carers to impact clinical research.

Claas Röhl, Chairman, NF Kinder, EUPATI Austria, NF PatientsUnited 

with:

Renata Lazarova, MD, VP Development, Pediatric Programs, Noema Pharma

Learn more about the Patients as Partners EU conference at www.patientsaspartners.org

Where have we come over the past 5 yearsWhat are the approvals and approval activity over the past year?What are the challenges and issues?What have we learned?What are the real important technologies that are being developed that might help transform the cell and gene therapy spaceWhat are the key things we need to think about moving forward?

Michael Kalos, PhD, Managing Director, Next Pillar Consulting

Learn more about the IO360° Summit at www.io360summit.com

Kate Woda, IO360° Conference Director, gives a 6 minute overview on what you can expect at the 9th annual IO360° Summit taking place February 7-10 in Brooklyn, NY.

Keynotes Include:

Dr Carolyn Bertozzi, Stanford University on Bioorthogonal and Click Chemistries Impact on Advancing Cancer ImmunotherapyDr Marcela Maus, Massachusetts General Hospital on Mechanisms Driving CAR T CellsDr Isabelle Rivière, Memorial Sloan Kettering Cancer Center on Cell Therapy Manufacturing Progress Report and Novel Manufacturing ParadigmsDr Axel Hoos, Scorpion Therapeutics on Transformational Medicines & The Next Wave of IODr Andrew Baum, Citi on What’s Next on the IO Radar? Top 10 RecommendationsDr Arjun Goyal, Vida Ventures on Investor Perspective on the State of the Current Market and Impact on the IO Cell Therapy FieldOswald Peterson, Stage IV Lung Cancer Survivor who will share his extraordinary story from diagnosis through to immunotherapy treatments that saved his life

Plenary Topics:

Biomarkers / Assay DevelopmentDiscovery / PreclinicalImaging AdvancementsClinical OperationsBusiness DevelopmentsTranslational ScienceCell TherapyRNA TherapeuticsClinical Developments

Learn more about the upcoming IO360° Summit at www.io360summit.com

There are many reasons why patients don’t trust or feel comfortable using a digital/mobile device. Implementing mobile technologies in clinical trials can sometimes create barriers to participation amongst patients who struggle to access them, are digitally challenged and/or do not have the bandwidth to support the utilization. This session addresses the digital divide, the challenges of accessing and using mobile technologies and solutions to reduce these barriers.

Patient and site perspectives on utilizing mobile/digital technologies in clinical trialsHow pharma is addressing access and equity from a digital perspectiveEducating, communicating and supporting patients through the use of digital/mobile technologies, reducing anxiety and building trustHow do we think about trial design to accommodate patients using digital/mobile technologiesHow are we addressing and tackling WiFI/Bandwidth connectivity challenges that are required with these technologies such as patient access?

Speakers:

Adama Ibrahim, VP, Digital Strategy and Change Management, Novo NordiskTina Aswani-Omprakash, Patient AdvocateMarieElena Cordisco MA, NP-C, APRN, AVP Clinical Trials, Research and Innovation, Nuvance HealthTimothy Joy, Head, Clinical Operations Strategic Solutions, PfizerJoan Severson, Chief Innovation Officer, Clinical InkAsh Rishi, CEO, COUCH Health